Updated cash guidance provides runway into at least the middle of calendar 2026 Company remains encouraged by MDNA11 clinical results presented to-date, demonstrating best-in-class potential of our IL-2 superkine by exceeding ORR benchmarks demonstrated with other competing therapies in similar checkpoint resistant tumor types A patient with pancreatic cancer and a melanoma cancer patient remain cancer free for 18 and 6... Read More

Granted patents provide broad composition, formulation, and method of use protection across key global markets including use of MDNA11 in combination with checkpoint inhibitors and a novel formulation of bizaxofusp TORONTO and HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing novel Superkines for... Read More

Updated cash guidance provides runway into at least mid-2026 MDNA11 Phase 1/2 clinical trial on track for data readouts in second half of the year as a single agent and in combination with KEYTRUDA ® at medical conferences and a planned KOL event MDNA11 continues to exhibit compelling deep and durable anti-tumor activity in difficult-to-treat solid tumors with best-in-class potential relative to competing IL-2 programs... Read More

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2 SK ), engineered to precisely deliver clinically validated anti-PD1 and IL-2 SK to the tumor microenvironment (TME) IL-13Rα2 is overexpressed by some of the most “immunologically cold” tumors with high unmet needs in pancreatic, liver, brain, breast, colon and prostate cancer that annually affect over 2 million patients worldwide... Read More

Ten (10) patients have achieved an objective response (5 confirmed) when treated with MDNA11 alone or in combination with KEYTRUDA® (pembrolizumab) – all responders had advanced and/or metastatic cancers with resistance to immune checkpoint inhibitors (ICI) or with historically low responses to ICI Combination of MDNA11 with KEYTRUDA in the dose escalation arm achieved an objective response rate (ORR) of 36% (5 of 14) in all... Read More

TORONTO and HOUSTON, April 22, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, today announced that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the 2025 Bloom Burton & Co.... Read More

TORONTO and HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, today announced that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the Jones Healthcare and Technology... Read More

Additional data from the MDNA11 ABILITY-1 trial to be presented at the Annual Meeting Pre-clinical data on Medicenna’s first-in-class Masked and Tumor Targeted Bifunctional anti-PD1-IL2 Superkine, MDNA113, will also be presented TORONTO and HOUSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the... Read More

MDNA11 significantly expands a unique population of ‘stem-like’ CD8+ T cells that leads to more persistent and effective anti-tumor activity MDNA11 has shown durable single agent activity, with a 30% (3 of 10) objective response rate (ORR) in the monotherapy dose expansion cohort in checkpoint-resistant patients (as of Dec. 5, 2024) Disease control rate (DCR) of 78% (7 of 9) in combination with Merck’s (known as MSD outside... Read More

Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck’s (known as MSD outside of Canada and the US) KEYTRUDA ® (pembrolizumab) in ongoing Phase 1/2 ABILITY-1 trial including one complete response, one partial response and five stable disease (as reported on Dec. 5, 2024) MDNA11 continued to demonstrate deep and durable single agent activity, with a 30% (3 of 10) objective response rate... Read More

TORONTO and HOUSTON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer, and inflammatory and autoimmune diseases, today announced that its management team will participate in two upcoming investor conferences in February 2025. The company will also... Read More

Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving long-term survival in an aggressive mouse model of triple negative breast cancer (TNBC) Mice treated with MDNA11 prior to surgery were able to mount powerful immune and memory response to subsequent tumor rechallenges, demonstrating potential to prevent new tumor growth... Read More

70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when treated with MDNA11 in combination with Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA ® (pembrolizumab) Complete regression of all tumors in two CPI-resistant patients in monotherapy arms continue to show durability with a patient with melanoma remaining tumor free at week 63 while... Read More

TORONTO and HOUSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that updated clinical data from the ongoing Phase 1/2 ABILITY-1 study will be presented as part of an oral podium presentation at the 2024 Immunotherapy Bridge Conference, taking place from... Read More

MDNA11 shows significant survival benefits in preclinical glioblastoma models, expanding CD8 + T and NK cells Bizaxofusp selectively targets human tumor cells and immune-suppressive cells, enhancing anti-tumor immunity Combination therapy with MDNA11 and Bizaxofusp demonstrates synergistic tumor-killing in human GBM tumoroids TORONTO and HOUSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or... Read More

MDNA11 continues to show best-in-class potential in the ABILITY-1 study with an objective response rate (ORR) of 30% in the monotherapy dose expansion cohort among patients with cancer progression after one or more immune checkpoint inhibitor (ICI) therapy Two PRs were observed among 3 microsatellite instability high (MSI-H) ICI resistant patients (ORR 66.7%) with both responders having pancreatic cancer including one... Read More

TORONTO and HOUSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it will present pre-clinical data on MDNA11 and IL-2 Superkines in glioblastoma models at the 29 th Annual Meeting of the Society of Neuro-Oncology (SNO) taking place in Houston, Texas... Read More

Single-agent MDNA11 shows a 30% objective response rate (3 of 10) in the monotherapy dose expansion cohort among patients with advanced and/or metastatic solid tumors who had disease progression with immune checkpoint inhibitor (ICI) therapy Among ICI-resistant, high-dose MDNA11, phase 2-eligible patients in the monotherapy escalation and expansion cohorts (N=20), the response rate is 25% (5/20) including 1 complete response... Read More

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2 SK ) to the tumor microenvironment (TME), where it is conditionally activated by tumor-associated proteases MDNA113 treatment achieved complete tumor regression of IL-13Rα2 expressing tumors, highlighting its potential to treat a vast range of malignancies,... Read More

Updated clinical results to be presented from the ongoing Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors Preclinical data on MDNA113, Medicenna's first-in-class, masked, tumor-targeted bifunctional anti-PD1-IL-2 Superkine, and on its IL-2 agonists in glioblastoma, will also be presented TORONTO and HOUSTON, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the... Read More

TORONTO and HOUSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced the voting results from the Company’s annual meeting of shareholders held today, September 26, 2024 (the “Meeting”). Medicenna is pleased to announce that all nominees listed in the management... Read More

MDNA209 is a first-in-class “beta-enhanced” IL-2 Super-antagonist being developed for the potential treatment of autoimmune diseases, a disorder attributed to an imbalance of the immune system and affecting 5 to 10% of the global population MDNA209 restores immune balance by selectively blocking IL-2Rβγ c , a receptor highly expressed by effector CD8 T cells which are known to promote tissue damage in autoimmune diseases In... Read More

TORONTO and HOUSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that Dr. Fahar Merchant, President and CEO of Medicenna, will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright 26 th Annual Global Investment Conference,... Read More

TORONTO and HOUSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that the Company will present two abstracts, both as oral presentations, at the Promise of Interleukin-2 Therapy Conference, taking place at the Centre International de Conférences Sorbonne... Read More

TORONTO and HOUSTON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today the appointment of Mr. Karim Lalji as a new addition to its Board of Directors effective as of August 14, 2024. “We are thrilled to announce the appointment of Mr. Karim Lalji as a new... Read More

Patient with melanoma, having failed dual check-point inhibitor therapy, achieved a complete response following treatment with MDNA11 at week 52 with 100% regression of all target and non-target lesions reinforcing its best-in-class potential Updated scans from pancreatic cancer patient continues to show sustained 100% regression of target and non-target lesions at 115 weeks and remains in remission 6 months after ending... Read More

Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity and best-in-class potential relative to other IL-2 therapies in clinical development Results presented at the Annual Meeting of the AACR showed single agent MDNA11 response rate of 29% (4/14) in patients with checkpoint resistant... Read More

ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a novel long-acting IL-2 super-agonist, as a monotherapy or in combination with KEYTRUDA ® , at clinical trial sites in U.S.A., Canada, Australia, and Korea Monotherapy expansion and combination escalation data of the ABILITY-1 study are expected in H2 2024 TORONTO and HOUSTON, June 26, 2024 (GLOBE NEWSWIRE) -- Medicenna... Read More

Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half (hazard ratio: 0.54, 95% confidence interval: 0.34-0.83) versus a propensity balanced external control (EC) arm irrespective of IL-4 receptor (IL-4R) expression in unresectable recurrent glioblastoma (rGBM) patients in the Phase 2b Study Bizaxofusp increased median overall... Read More

MDNA11 demonstrates durable response in pancreatic cancer patient with 100% regression of target and non-target lesions for over 104 weeks and continues to show remission 4 months after stopping treatment Melanoma patient continues to show sustained 100% regression of target lesions Dose escalation in combination with KEYTRUDA® is now enrolling at the next higher dose of 90g/kg following absence of any dose limiting... Read More

TORONTO and HOUSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it will present an update on the MDNA11 ABILITY-1 Trial at the Sachs 10 th Annual Oncology Innovation Forum . The forum takes place on Friday, May 31 st , 2024, as part of the clinical... Read More

ASCO has informed the Company that the previously accepted MDNA11 oral abstract has been withdrawn due to alleged violation of their prior publication policy based solely on their review of the abstract presented at AACR 2024. Medicenna disagrees with ASCO’s decision as the AACR 2024 abstract was limited to on-going interim... Read More

TORONTO and HOUSTON, April 30, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA) (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineered cytokines, announced today the closing of its previously announced CA$20 million investment by RA Capital Management, a multi-stage investment manager based in Boston, MA, by way of a non-brokered private... Read More

TORONTO and HOUSTON, April 26, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA) (MDNAF: OTCQB), a clinical-stage immunotherapy company focused on the development of engineered cytokines, today announced a CA$20 million investment by RA Capital Management, a multi-stage investment manager based in Boston, MA, by way of a non-brokered private placement (the “Offering”). Medicenna... Read More

Oral presentation of MDNA11’s Phase 1/2 ABILITY-1 Study will feature new and updated clinical data Updated bizaxofusp survival results from the Phase 2b recurrent glioblastoma trial versus propensity matched external control arm will also be presented as a poster TORONTO and HOUSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage... Read More

100% reduction of target lesions in one melanoma and one pancreatic cancer patient observed among 4 Partial Responses (PR) to date which include 2 of 4 evaluable dose expansion patients and 2 of 2 MSI-H patients Durable stable disease (SD) in 3 melanoma patients for 6 to 18 months with concomitant tumor shrinkage With response rate and clinical benefit rate increasing to 29% and 50% (4 PR, 3 SD), respectively, MDNA11... Read More

MDNA113 is targeted to the tumor site where it is activated to simultaneously deliver two immunotherapies, an IL-2 superkine and anti-PD1 antibody, to the same cancer fighting immune cells in the tumor micro-environment (TME) to maximize efficacy and minimize systemic toxicity MDNA113 is our most advanced pre-clinical candidate that targets IL-13Rα2, a tumor associated antigen, which is overexpressed by immunologically... Read More

TORONTO and HOUSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that Dr. Fahar Merchant, President and CEO of Medicenna, will present and participate in one-on-one meetings at the 2024 Bloom Burton & Co. Healthcare Investor Conference, which is... Read More

TORONTO and HOUSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that two posters will be presented at the American Association for Cancer Research Annual Meeting 2024 (AACR 2024), taking place in San Diego, CA from April 5-10, 2024. The Company will... Read More

With the Response Rate increasing to 23%, MDNA11 continues to show compelling single-agent activity in the ABILITY-1 study amongst high-dose phase-2 eligible patients (N=13) that failed checkpoint inhibitor therapies, while maintaining an acceptable safety profile Tumor shrinkage was also observed in all high-dose phase-2 eligible patients with stable disease (SD). In addition to a new PR, the clinical benefit rate (PR plus... Read More

The ABILITY-1 Study is evaluating MDNA11, a highly selective long-acting IL-2 Superkine, in combination with KEYTRUDA ® (pembrolizumab) for treatment of patients with advanced solid tumors MDNA11 continues to demonstrate encouraging single-agent activity from the monotherapy dose escalation portion of the ABILITY-1 Study Company expects to report results from both the monotherapy expansion and combination escalation and... Read More

TORONTO and HOUSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced the appointment of MNP LLP (“MNP” or “Successor Auditor”) as auditor. The board of directors of the Company accepted the resignation of PricewaterhouseCooper LLP (the “Former Auditor”) and... Read More

The ABILITY-1 Study will evaluate MDNA11, a highly selective long-acting IL-2 Superkine, in combination with KEYTRUDA ® (pembrolizumab) for treatment of patients with advanced solid tumors MDNA11 continues to demonstrate encouraging single-agent activity from the dose escalation portion of the ABILITY-1 Study MDNA11 is generally well tolerated with no dose-limiting toxicities or vascular leak syndrome reported in any of the... Read More

TORONTO and HOUSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical stage immunotherapy company focused on the development of Superkines, today announced that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date of the common share purchase warrants of the Company (the “Warrants”) originally issued... Read More

TORONTO and HOUSTON, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that its shares will commence trading on the OTCQB Venture Market in the United States, effective December 19, 2023. Medicenna’s shares will continue to trade on the Toronto Stock Exchange... Read More

Single treatment of bizaxofusp doubled mOS (14.5 months vs. 7.2 months) irrespective of IL4R expression (high or low) compared to patients treated in the external control arm Survival for bizaxofusp-treated patients increased 370% at Year 1 and increased more than 50% at Year 2 TORONTO and HOUSTON, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a... Read More

Cash runway extended through multiple data readouts and into Q1 of calendar 2025 MDNA11 is generally well tolerated and continues to demonstrate encouraging single-agent activity from Phase 1 portion of the ABILITY-1 Study including 100% and 70% reduction of target lesions in pancreatic and melanoma cancer patients, respectively Four-year follow-up survival results from Phase 2b bizaxofusp (MDNA55) study in patients with... Read More

TORONTO and HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTC: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that a poster presentation and an oral summary highlighting long-term follow up from the Phase 2b clinical trial of bizaxofusp (formerly known as MDNA55), the Company’s first-in-class IL-4R... Read More

MDNA11 continues to demonstrate encouraging single-agent activity from the dose escalation and evaluation portion of the ABILITY-1 Study including deep ongoing partial responses with 100% reduction of target lesions in one pancreatic and 70% reduction of target lesion in one melanoma cancer patient MDNA11 also showed durable stable disease in 3 melanoma patients for at least 5 months to 18 months with concomitant shrinkage... Read More

Company’s T-MASK platform demonstrates ability to maximize anti-tumor efficacy and minimize systemic toxicity, and opportunities to explore broad range of cytokines and other potent therapeutics MDNA113 is a first-in-class IL-13R⍺2 targeted therapy that delivers a masked bi-specific IL-2-AntiPD1 Superkine to the tumor micro-environment where it is activated by cancer specific enzymes IL-13Rα2 is overexpressed by some of the... Read More

TORONTO and HOUSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of engineered cytokines, announced today that the Company received a Staff Delisting Determination from the Listing Qualifications Department of the Nasdaq Stock Market, LLC (“Nasdaq”), which notified the Company of the... Read More

New data from the Phase 1 dose-escalation and evaluation portion of the trial will be presented at the Society of Immunotherapy for Cancer (SITC) Annual Meeting on November 4, 2023 Company expects to report initial results from both the monotherapy and combination arms of the Phase 2 dose expansion study in H1 2024 TORONTO and HOUSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the... Read More

TORONTO and HOUSTON, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of Superkines, announced poster presentations at the 38 th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) to be held in San Diego, CA, from November 1-5 th , 2023. The company will present an update from... Read More

TORONTO and HOUSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced the appointment of Humphrey Gardner, M.D., as Chief Medical Officer (CMO) to lead the development strategy and execution of Medicenna’s clinical programs. “We are thrilled to welcome... Read More

MDNA223 is a bifunctional Superkine designed to activate cancer-killing immune cells via the IL-2 receptor while simultaneously preventing their exhaustion by blocking PD-1 signalling MDNA223 demonstrated superior efficacy and extended survival in multiple immunologically “hot” and “cold” syngeneic tumor models MDNA223 showed synergy with pro-inflammatory agonist (STING) to enhance tumor inhibition and induce abscopal effect... Read More

TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ, TSX: MDNA), a clinical-stage immuno-oncology company focused on the development of novel Superkines, today announced the voting results from the Company’s annual and special meeting of shareholders held today, September 28, 2023 (the “Meeting”). Medicenna is pleased to announce that all of the nominees... Read More

TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, announced that the Company will present preclinical results featuring its MDNA223 BiSKIT candidate at the 2023 AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy to be held... Read More

TORONTO and HOUSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, announced that Dr. Fahar Merchant, President and CEO is scheduled to participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023, at 2:30 PM... Read More

Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella’s appointment demonstrates Medicenna’s continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”)... Read More

Company to grow business development, financing and clinical leadership in Boston by accessing top-biotech talent. Brent Meadows, MBA, joins as Chief Business Officer (CBO), bringing over 25 years of large pharma and biotech experience and a track record of multiple high-value transactions in oncology and immuno-oncology. After over 6 years as CFO, Ms. Elizabeth Williams has chosen to pursue another biotech opportunity. A... Read More

Durable anti-cancer activity was observed during monotherapy dose escalation without dose-limiting toxicities Late-stage pancreatic cancer patient achieved 80% tumor shrinkage with complete regression observed in two of three metastatic lesions in the liver in response to single-agent MDNA11 Immune pharmacodynamic data continues to support a differentiated mechanism with preferential expansion of potent cancer-fighting... Read More

TORONTO and HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today the appointment of Dr. Arash Yavari as the Chair of its Development Advisory Committee (“DAC”), a team comprised of industry veterans in immuno-oncology drug development and regulatory strategy. “We are pleased to welcome Dr. Arash... Read More

TORONTO and HOUSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical-stage immunotherapy company, announced today that it will host a conference call and live webcast on August 9, 2023 at 8:30AM ET to provide a clinical update from the Phase 1/2 ABILITY study evaluating MDNA11 in patients with melanoma and other select tumors. Shareholders and... Read More

Medicenna Therapeutics Corp. has been granted U.S. Patent No. 11,680,090 titled “Interleukin-2 Fusion Proteins and Uses Thereof.” The patent covers a method for enhancing immune cell survival and proliferation or inhibiting cell death and therefore improving fitness of cancer fighting immune cells. TORONTO and HOUSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA... Read More

Safety Review Committee clears MDNA11 Cohort 6 dose of 120µg/Kg, Q2W, in the Phase 1 portion of the ABILITY Study as there were no protocol defined dose-limiting toxicities MDNA11 clinical update scheduled for August 9; conference call to discuss data from cohorts five and six, recommended dose for monotherapy expansion and details on Phase 2 trial design $29.6 million in cash and cash equivalents as of June 30, 2023... Read More

Medicenna's President and CEO, Dr. Fahar Merchant, was invited to participate and present at the Brain Cancer Research Roundtable organized by the National Brain Tumor Society (“NBTS”) The focus of the event was to explore ways to expedite development of novel therapies for brain cancer by leveraging real-world patient data as External Control Arms (“ECA”) TORONTO and HOUSTON, July 25, 2023 (GLOBE NEWSWIRE) -- Medicenna... Read More

TORONTO and HOUSTON, July 05, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date of a total of 1,549,052 outstanding common share purchase warrants of the Company (the “Warrants”) originally issued on October 17,... Read More

MDNA11 demonstrates durable single-agent activity in forth-line metastatic pancreatic cancer patient with a partial response continuing for over 40 weeks and stable disease for over 70 weeks as a third-line treatment in a patient with metastatic melanoma MDNA11 clinical update is anticipated during calendar Q3 2023, for all dose escalation patients including high dose cohorts five and six including outcomes from safety... Read More

TORONTO and HOUSTON, April 27, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that on April 25, 2023 it received a notice (the “Extension Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) granting the Company’s request for a 180-day extension to regain compliance with the minimum bid price requirement... Read More

TORONTO and HOUSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that Dr. Fahar Merchant, President and CEO of Medicenna, will participate in a fireside chat and management will participate in one-on-one meetings at the 2023 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled... Read More

IL-13 Superkines provide a versatile strategy for targeted delivery of anti-cancer agents to IL-13Rα2, which is overexpressed in many solid tumors but minimally expressed in normal tissues MDNA132 and MDNA213 are novel IL-13 Superkines that are highly specific and preferentially accumulate in the microenvironment of IL-13Rα2-expressing tumors L-13 Empowered Superkines™ act synergistically in combination with IL-2 Superkines... Read More

Additional evidence of durable anti-cancer activity with MDNA11 monotherapy seen in latest radiographic scans from first four dose escalation cohorts Continued tumor reduction and complete regression of one of three metastatic lesions in fourth-line pancreatic cancer patient with confirmed partial response Stable disease maintained for more than 70 weeks in patient with metastatic melanoma MDNA11 continues to selectively and... Read More

TORONTO and HOUSTON, March 15, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the publication of an abstract that has been accepted for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place at the Orange County Convention Center in Orlando,... Read More

TORONTO and HOUSTON, March 02, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participate in a fireside chat at the Oppenheimer 33 rd Annual Healthcare Conference, which is scheduled to take place virtually from March 13 –... Read More

TORONTO and HOUSTON, Feb. 17, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, announced today that it has entered into a sales agreement with Oppenheimer & Co. Inc. (“Oppenheimer & Co.”) acting as sales agent (the “Sales Agreement”), pursuant to which the Company may, from time to time, sell through “at-the-market”... Read More

Phase 1/2 ABILITY study advancing to sixth dose escalation cohort following positive review of safety and pharmacodynamic data from fifth cohort Initial PK/PD data from ABILITY’s fifth dose escalation cohort expected alongside updated anti-tumor data in calendar Q1 2023 $36.2 million in cash and cash equivalents at December 31, 2022 provides expected runway through the completion of the ABILITY study and through calendar Q2... Read More

TORONTO and HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participate in a fireside chat at the 2023 Guggenheim Oncology Conference, which is scheduled to take place from February 8 – 9, 2023. Details... Read More

TORONTO and HOUSTON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on February 7, 2023 at 8:30 AM ET to report its third quarter fiscal 2023 financial results and operational highlights. To access the call, please dial 1-877-407-9716 from... Read More

Patent covers methods of treating cancer with an IL-2 Superkine and PD1/PDL1 or CTLA-4 checkpoint inhibitor, administered in combination or as a single agent BiSKIT™ TORONTO and HOUSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S.... Read More

Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that on October 25, 2022, it received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company is not in compliance with the minimum bid price requirement ("Minimum Bid Requirement") of US$1.00 per share under the Nasdaq Listing Rule 5450(a)(1)... Read More

Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on November 4, 2022 at 8:30 AM ET to report its second quarter fiscal 2023 financial results and operational highlights. To access the call, please dial 1-877-407-9716 from Canada or the United States or 1-201-493-6779... Read More

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced the acceptance of two abstracts for poster presentations at the Society for Immunotherapy of Cancer (SITC) 37 th Annual Meeting, which is taking place both virtually and in-person at the Boston Convention and Exhibition Center in Boston, MA, from November 8 – 12, 2022. Both abstracts... Read More

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date of the common share purchase warrants of the Company (the “Warrants”) originally issued on October 17, 2019. The Warrants, of which 1,549,052 are available to be extended, are... Read More

Confirmed partial response in fourth-line metastatic pancreatic cancer patient, who had previously failed chemotherapy and checkpoint inhibitor therapy, supports MDNA11’s single-agent potential in advanced solid tumors unresponsive to established treatments The observed tumor control rate of 36% in the low and mid-dose cohorts (n=14) in patients with advanced metastatic cancer further enhances our confidence in MDNA11’s... Read More

Single agent Anti-PD1-IL-2 BiSKIT™ showed superior efficacy compared to a combination of an anti-PD1 antibody with an IL-2 Superkine in murine models of colon, skin, and breast cancer IL-4/IL-13 Super-antagonist displayed monotherapy activity in multiple cancer models and in synergy with an IL-2 Superkine, highlighting its potential to treat immunologically “cold” tumors Medicenna Therapeutics Corp. (“Medicenna” or “the... Read More

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the voting results from the Company’s annual meeting of shareholders held today, September 21, 2022 (the "Meeting"). Medicenna is pleased to announce that all of the nominees listed in the management proxy circular dated August 2, 2022 were elected as directors. Each of the directors... Read More

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada) to evaluate MDNA11, Medicenna’s “beta-only” long-acting IL-2 super-agonist in combination with KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1... Read More

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that the Company management and scientific teams will present at the following investor and scientific conferences this month: H.C. Wainwright 24 th Annual Global Investment Conference An on-demand corporate presentation will be available here and on the “ Investor Relations ” section... Read More

Extended Cash Runway Into 2024 With US$20 Million Raise To Complete Phase 1/2 ABILITY Study And Advance Pipeline New MDNA11 Data From Dose Escalation in ABILITY Study Shows Tumor Control In Four Of Ten Evaluable Patients Including Unconfirmed Partial Response In Pancreatic Cancer Patient ABILITY Study Commences Enrolling In Its Fifth Dose Escalation Cohort With No Dose-Limiting Toxicities Reported To Date Additional Clinical... Read More

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immunotherapy company, is pleased to announce the closing of its previously announced marketed underwritten public offering of units (the “Units”) of the Company in Canada and in the United States at a price to the public of US$1.50 per Unit (the “Offering”), for aggregate gross proceeds to the Company of approximately... Read More

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical stage immunotherapy company, announced today that it has priced its previously-announced marketed underwritten public offering of 13,333,334 units (the “Unit”) of the Company in the Canada and in the United States at a price to the public of US$1.50 per Unit (the “Offering”). The gross proceeds to the Company from the Offering... Read More

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA, TSX: MDNA), a clinical stage immunotherapy company, announced today the launch of a marketed underwritten public offering of units of the Company (the “Units”) in the United States (the “Offering”). Each Unit will be comprised of one common share and one warrant to purchase common shares (a “Warrant” and, collectively, the “Warrants”). The Offering is... Read More

Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on August 15, 2022 at 8:30 AM ET to report its first quarter fiscal 2023 financial results and operational highlights. To access the call, please dial 1-877-407-9716 from Canada or the United States or 1-201-493-6779... Read More

Tumor control was achieved in four of ten evaluable patients with advanced solid tumors unresponsive to other treatments enrolled in the ABILITY Study’s low and mid-stage dose escalation cohorts Study’s fifth dose-escalation cohort is open for enrollment following a favorable review of safety data from Cohort 4 by the trial’s Safety Review Committee Data featured in an oral presentation taking place at 1:00 PM ET today at... Read More

Cash runway extended late into calendar Q2 2023 Tumor control achieved following MDNA11 treatment in 3 out of 8 patients enrolled in first 3 dose escalation cohorts of the ABILITY Phase 1/2 Study. Pharmacodynamic data show superior dose-dependent increase in stimulation of anti-cancer immune cells when compared to competing IL-2 programs in the clinic Management hosting conference call and webcast today at 8:30 AM ET... Read More

Patent covers composition and methods of treating degenerative diseases via administration of IL-4 and IL-13 Empowered Superkines Delivery of selected Bcl-2 family of proteins can prevent cell death, repair cell damage and restore cellular function in various diseases. Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced that the U.S.... Read More

Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on June 22, 2022 at 8:30 AM ET to report its fiscal year 2022 financial results and operational highlights. To access the call, please dial 1-877-407-9716 from Canada or the United States or 1-201-493-6779 internationally, followed... Read More

New data show that MDNA11 boosted the lymphocyte population by 2-fold without inducing significant increases in eosinophils (associated with toxicity) MDNA11 selectively increased a sub-population of anti-tumor ICOS + CD8 T cells without enhancing proliferation of highly immune-suppressive pro-tumor ICOS + Treg cells Dose-dependent and 3-fold increase in immune cells expressing Granulysin, a peptide known to target tumor... Read More

-Levels of Ki67 + expression by CD8 + T cells and NK cells increased by 17-fold and 10-fold, respectively, in the third cohort (30 µg/kg dose) when compared to baseline -NK cell / Treg and CD8 + T cell / Treg ratios increased by 4.4-fold and 2.6 fold, respectively, at the 30 µg/kg dose, demonstrating superior stimulation of cancer fighting immune cells. -Significant dose-dependent increases in CD8 + T (>3-fold) and NK... Read More

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President and CEO and Elizabeth Williams, CFO of Medicenna, will attend the conference and present a corporate overview at the 2022 Bloom Burton & Co. Healthcare Investor Conference, which is scheduled to take place from May 2 – May 3, 2022. Details are as... Read More

Anti-PD1-IL-2 BiSKIT ( Bi -functional S uper K ines for I mmuno T herapy) selectively stimulates anti-cancer immune cells via IL-2 agonism and prevents their exhaustion through PD-1 inhibition Treatment with anti-PD-1-IL-2 BiSKIT led to statistically significant improvements in tumor growth inhibition and survival compared to the co-administration of its underlying components Data highlight the versatility of the Superkine... Read More

Fc-MDNA413 suppresses pro-tumor immune pathways by simultaneously inhibiting IL-4 / IL-13 mediated signaling and proliferation via the Type II IL-4 receptor Fc-MDNA413 inhibits in vivo tumor growth alone and in combination with an IL-2 super-agonist in a murine cancer model Ability of Fc-MDNA413 to selectively block Type II IL-4 receptor activity in the tumor micro-environment (TME) may be effective in treating... Read More

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will present a corporate overview at the 32 nd Annual Oppenheimer Healthcare Conference, which is scheduled to take place virtually from March 15 – March 17, 2022. Details are as follows: 32 nd Annual... Read More

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the publication of two abstracts that have been accepted for electronic poster presentations at the American Association for Cancer Research (AACR) Annual Meeting, which is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans, Louisiana... Read More

Medicenna’s Clinical Advisory Board is comprised of thought leaders in immuno-oncology with experience in clinical development of Proleukin® and next generation IL-2 Dr. Dhingra has a track record of development and approval of cancer therapies and extensive board level expertise resulting in multiple transactions with pharma Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical... Read More

Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participate in a Fireside Chat at the SVB Leerink Global Healthcare Conference, which is scheduled to take place virtually from February 14 – February 18, 2022. Details are as follows: 11 th Annual... Read More

Phase 1/2 ABILITY study of MDNA11 on track with first set of efficacy results from early dose escalation cohorts expected in mid-calendar 2022 Preliminary pharmacodynamic data show preferential stimulation of anti-cancer immune cells with MDNA11 treatment in the ABILITY study First clinical site in the US open for enrolment Management hosting conference call and webcast today at 8:30 am ET Medicenna Therapeutics Corp.... Read More

MDNA11 demonstrates a 30-fold increase in affinity for IL-2 receptor beta without binding to IL-2 receptor alpha when compared to recombinant human IL-2 MDNA11 was well-tolerated and induced durable proliferation and expansion of anti-cancer immune cells with limited stimulation of pro-tumor Treg cells in non-human primates MDNA11 alone or in combination with a checkpoint inhibitor generated durable complete responses and... Read More

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Mann Muhsin has resigned as Chief Medical Officer of the Company to assume a position closer to home. Martin Bexon, MBBS, who has managed many aspects of Medicenna’s clinical programs since 2016, will serve as Acting Chief Medical Officer in addition to his current role as the... Read More

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that company management will be participating in the following virtual investor conferences taking place in January 2022. Details are as follows: 11 th Annual LifeSci Partners Corporate Access Event (January 5 – 7, 2022) Format: Panel Presentation and 1x1 investor meetings Panel... Read More

Peak CD8 + T cell (anti-tumor) / Treg (pro-tumor) ratio increased ~2-3 fold over baseline with MDNA11 treatment in the trial’s first two dose escalation cohorts MDNA11-induced increases in CD8 + T and NK cells compare favorably to competing IL-2 variants in the clinic No dose limiting toxicity, or any evidence of cytokine release syndrome, nor any evidence of vascular leak syndrome has been observed Medicenna Therapeutics... Read More

ABILITY Study is currently ongoing at clinical trial sites in Australia and previously received FDA clearance to expand to sites in the United States Preliminary update on safety and PK/PD data expected by year-end 2021 Initial efficacy data update expected in mid-2022 Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Health... Read More

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that John H. Sampson, MD, PhD, MHSc, MBA, Robert H. and Gloria Wilkins Distinguished Professor of Neurosurgery at Duke University School of Medicine and member of Medicenna’s Board of Directors, received The Abstract Award for Excellence in Clinical Trials in connection with an... Read More

Phase 1/2 ABILITY Study of MDNA11 on track for preliminary data updates in calendar 2021 and mid-calendar 2022 Management hosting conference call and webcast today at 8:30 am ET Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today provided a business update and announced its financial results and operational highlights for the quarter ended... Read More

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will be presenting a corporate overview at Stifel’s Virtual Healthcare Conference on Monday, November 15, 2021. Details are as follows: Event: Stifel Virtual Healthcare Conference Format: Corporate... Read More

Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on November 12, 2021 at 8:30 AM ET to report its second quarter 2022 financial results and operational highlights. To access the call, please dial (877) 407-9716 from the United States or (201) 493-6779 internationally, followed by... Read More

ABILITY Study is currently ongoing at clinical trial sites in Australia Preliminary update on safety, PK/PD, and biomarker data expected by year-end 2021 Initial efficacy data update expected in mid-2022 Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ/TSX: MDNA), a clinical stage immuno-oncology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared Medicenna’s... Read More

MDNA11 preferentially induced durable proliferation and expansion of anti-cancer immune cells with limited stimulation of pro-tumor Treg cells in non-human primates (NHP) MDNA11 administration in NHPs did not lead to safety issues typically associated with IL-2 MDNA11 alone or in combination with anti-PD1 checkpoint inhibitor resulted in 100% tumor control and long-term protection against tumor re-challenge by inducing... Read More

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the appointment of John H. Sampson, MD, PhD, MBA, to its Board of Directors and the voting results from the Company’s annual meeting of shareholders held today, September 23, 2021 (the "Meeting"). “John is a world-renowned clinician-scientist and I’m thrilled to welcome him to our... Read More

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that members of its leadership team will participate in the Next-Gen Cytokine Therapeutics Summit today. Dr. Fahar Merchant, President and CEO of Medicenna, will deliver a presentation entitled, “Evolutionary IL-2 Superkines: Past, Present and Future” at 2:50 pm EDT. In addition to... Read More

Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that the US Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,117,943, titled “Superagonists and Antagonists of Interleukin-2.” The patent provides intellectual property (IP) protection for methods of treating a wide range of cancers specified in the claims with... Read More

Trial designed to assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of MDNA11 in patients with advanced solid tumors Preliminary update on safety, PK/PD, and biomarker data expected by year-end 2021 Preliminary efficacy readouts from study expected over the course of 2022 Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology... Read More

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will be presenting at the following virtual investor conferences to take place in September, 2021. Details are as follows: H.C. Wainwright 23 rd Annual Global Investment Conference Format: On demand... Read More

-- Phase 1/2 ABILITY Study of MDNA11 in patients with advanced solid tumors remains on track for initiation in the third quarter of calendar 2021 -- Management hosting conference call and webcast today at 8:30 AM ET TORONTO and HOUSTON, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial... Read More

TORONTO and HOUSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on August 13, 2021 at 8:30 AM ET to report its first quarter fiscal 2022 financial results and operational highlights. To access the call, please dial (877) 407-9716 from the... Read More

Phase 1/2 ABILITY Study is designed to evaluate MDNA11, a potentially best-in-class IL-2 Superkine, in patients with advanced solid tumors Study to start enrollment in the third quarter of 2021 in Australia, with expansion to additional sites in the US, UK and Canada Presentation by management team to take place today, July 27, 2021, at 2:00 p.m. ET Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA... Read More

Preclinical results in a pancreatic cancer model show that MDNA109, delivered by an oncolytic adenovirus, induced superior anti-tumor response with tendency towards complete tumor regression, improved survival, and long-term immune memory effect The data highlight the ability of MDNA109 armed oncolytic virus to reshape the tumor microenvironment from an immunosuppressive to a pro-inflammatory one and its potential to treat... Read More

Initiation of the ABILITY Study, a first-in-human trial, is expected in the third quarter of 2021 Trial is designed to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of MDNA11 in patients with advanced solid tumors Preliminary update on safety, PK/PD, and biomarker data expected by year end Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a... Read More

Management hosting conference call and webcast today at 8:30 AM ET Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the fiscal year ended March 31, 2021. All dollar amounts are expressed in Canadian currency unless otherwise noted. “The strong momentum we have generated over the... Read More

Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on May 28, 2021 at 8:30 AM ET to report its financial results for the fiscal year ended March 31, 2021 and operational highlights. To access the call, please dial (877) 407-9716 from Canada or the United States or (201) 493-6779... Read More

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the appointment of Mann Muhsin, MD, as the Company’s Chief Medical Officer. “Mann’s expertise in clinical trial design, execution and in-depth knowledge of the immuno-oncology therapeutic landscape, including IL-2, adds considerable depth to our diverse and highly talented management... Read More

Data published in Clinical Cancer Research indicate that early determination of PFS with modified RANO criteria may be a strong surrogate for overall survival in recurrent glioblastoma Medicenna’s proposed patient population shows a tumor control rate of 81% (26/32) based on modified RANO criteria Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company,... Read More

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the appointment of Kevin Moulder, PhD, as the Company’s Chief Scientific Officer (CSO). “Kevin is an ideal addition to our management team given his extensive experience leading drug discovery and development efforts in areas such as oncology and immunology,” said Fahar Merchant,... Read More

Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will present a corporate overview at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20th, 2021, at 10:00 AM ET. A live webcast of the virtual presentation may be accessed here . A... Read More

-- The IL-2/IL-13 dual specific cytokine selectively stimulates anti-cancer immune cells and inhibits M2a polarization of pro-tumoral macrophages -- Data demonstrate the potential to overcome immunotherapy resistance mechanisms and treat immunologically “cold” tumors TORONTO and HOUSTON, April 12, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage... Read More

MDNA11 and anti-PD-1 combination leads to complete responses in a murine solid tumor model Preclinical data demonstrates the potential of BiSKITs TM ( Bi -functional S uper K ine I mmuno T herapie s ) to effectively target immunologically “cold” tumors Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced an upcoming oral presentation... Read More

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the publication of an abstract for an electronic poster that will be presented during Week 1 of the American Association for Cancer Research (AACR) Annual Meeting 2021, taking place virtually from April 10-15, 2021. The poster will describe early preclinical studies evaluating a... Read More

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will be presenting at the H.C. Wainwright Global Life Sciences Conference and at the Oppenheimer 31 st Annual Healthcare Conference, as well as participating in a live panel discussion at the Maxim 2021... Read More

Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will present a corporate overview at the 41 ST Annual Cowen Healthcare Conference on Tuesday, March 2, 2021, at 2:10 PM ET. A live webcast of the presentation may be accessed here . A replay of the... Read More

Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will present a corporate overview at the 10 th Annual Leerink Global Healthcare Conference on Friday, February 26 th , 2021, at 3:00 PM ET. A live webcast of the presentation may be accessed by visiting... Read More

Medicenna Therapeutics Corp. ("Medicenna" or “Company") (NASDAQ: MDNA, TSX: MDNA), a clinical stage immuno-oncology company, today announced its financial results and operational highlights for the quarter ended December 31, 2020. All dollar amounts are expressed in Canadian currency unless otherwise noted. “Last quarter we achieved key regulatory milestones across our pipeline that position us for what we expect to be a... Read More